ReviewJornal brasileiro de nefrologia
Visceral leishmaniasis in kidney transplant recipients and candidates: an integrative review of the last 20 years.
Review in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Repurposing of Clomiphene Citrate and Its Antileishmanial and Antifungal Activities:Biomolecules · 2026Article
- Histoplasmosis in kidney transplant recipients.BMC nephrology · 2026Review
- Revisiting visceral leishmaniasis in immunocompromised patients: Ongoing gaps and advances in diagnostics, therapies, and preventive measures.Current research in parasitology & vector-borne diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLeishmaniasis is a potential concern for solid organ transplant (SOT) recipients, particularly those from endemic regions. Among SOT procedures, kidney transplantation (KT) is the most common. This study aims to synthesize the evidence about visceral leishmaniasis (VL) in KT candidates and recipients, with a focus on risk factors and associated outcomes.
methodsThis integrative review analyzed studies from the past 20 years, focusing on disease profile, treatment, prognosis, and risk of asymptomatic infection.
resultsA total of 32 articles were included. Of the KT recipients, 85.7% were male, with an average age of 42.5 years. The average timespan since symptom onset was 54.7 months. Renal function impairment was reported in 64% of patients, with an associated mortality rate of 15%. Post-treatment relapse occurred in 10-37.5% of patients. Among KT candidates, 13.9% were seropositive for Leishmania spp.
conclusionVL is an infrequent condition among KT recipients, limiting the quality of the available evidence. Early detection and prompt treatment are crucial for improving outcomes. While renal function impairment is common, it rarely leads to graft rejection. In the reviewed studies, the coexistence of VL and cutaneous or mucocutaneous forms was linked to higher mortality. Recurrences are common and require individualized management strategies. Hemotransfusion poses a potential infection risk, although routine screening in blood banks is not yet recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.